Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Ubamatamab Monotherapy Elicits Responses in Heavily Pretreated Ovarian Cancer

October 18th 2022

Ubamatamab monotherapy produced early clinical activity and an acceptable risk/benefit profile in heavily pretreated patients with ovarian cancer.

Dr. Karlan on Current Research Evaluating PARP Inhibitor Combination Therapy in Ovarian Cancer

October 18th 2022

Beth Y. Karlan, MD, discusses the current landscape of research investigating the efficacy of PARP inhibitor combination therapies for the treatment of patients with ovarian cancer.

Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial

October 17th 2022

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer

October 17th 2022

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

Mirvetuximab Soravtansine Generates Improvement in PROs Vs Chemotherapy in Advanced Ovarian Cancer

October 13th 2022

Treatment with mirvetuximab soravtansine elicited a statistically significant benefit vs investigator’s choice of chemotherapy for the OV28 abdominal/gastrointestinal symptom subscale in patients with folate receptor alpha–positive, advanced ovarian cancer.

Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status

October 12th 2022

González-Martín discusses the updated long-term efficacy and safety data from the PRIMA study, the importance of utilizing PARP inhibitors in patients with homologous recombination–deficient tumors, and the benefit observed with niraparib in those with homologous recombination–proficient tumors.

Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer

October 11th 2022

Antonio Gonzalez-Martin, MD, PhD, discusses new long-term progression-free survival data from the phase 3 PRIMA trial in advanced ovarian cancer.

PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial

October 6th 2022

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Recent Updates in PARP Inhibitor Indications for Ovarian Cancer

October 6th 2022

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Dr. Wenham on the Importance of Clinical Trials in Ovarian Cancer

September 30th 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.

Gavo-cel Elicits Clinical Benefit in Solid Tumors, Including Ovarian Cancer and Mesothelioma

September 28th 2022

Gavocabtagene autoleucel demonstrated positive topline results from the phase 1 portion of a phase 1/2 trial in patients with mesothelin-expressing solid tumors.

Pafolacianine Detects Microlesions in Folate Receptor–Positive Ovarian Cancer

September 27th 2022

Pafolacianine used during ovarian cancer surgery identified additional tumors that were not detected with conventional means and not otherwise planned for resection, according to results from a phase 3 study recently published in the Journal of Clinical Oncology.

Physicians Lose Access to 3 PARP Inhibitors for Heavily Pretreated, BRCA-Mutated Advanced Ovarian Cancer

September 23rd 2022

Manufacturers of 3 PARP inhibitors—niraparib, olaparib, and rucaparib—have voluntarily withdrawn indications for heavily pretreated patients with BRCA-mutated ovarian cancer due to safety concerns.

China Green Lights Olaparib for First-line Maintenance in HRD+ Advanced Ovarian Cancer

September 22nd 2022

Olaparib plus bevacizumab was approved in China as a first-line maintenance treatment for homologous recombination deficiency–positive ovarian cancer following a response to platinum-based chemotherapy plus bevacizumab.

Niraparib Maintenance Provides Durable Long-term Remission in High-Risk Advanced Ovarian Cancer

September 15th 2022

Maintenance treatment with niraparib produced a sustained and durable progression-free survival benefit in patients with primary advanced ovarian cancer who responded to first-line platinum-based chemotherapy, spanning biomarker subgroups.

Benchmarks in Clinical Trial Design Require Closer Examination by Oncologists

September 14th 2022

Maurie Markman, MD, elaborates on the need to take a closer look at the benchmarks used in clinical trial designs in oncology.

FDA and EU Approval Sought for Rucaparib as Frontline Maintenance in Select Advanced Ovarian Cancer

September 13th 2022

A supplemental new drug application and a Type II variation has been submitted to the FDA and the European Medicines Agency, respectively, seeking the approval of rucaparib as frontline maintenance treatment in women with advanced ovarian cancer irrespective of biomarker status who have responded to first-line platinum-based chemotherapy.

CLDN6 CAR T-Cell Therapy Shows Encouraging Efficacy in Relapsed/Refractory Advanced Solid Tumors

September 9th 2022

The investigational carcinoembryonic antigen claudin 6 (CLDN6)–directed CAR T-cell therapy BNT211-01 displayed clinical activity both as monotherapy and in combination with a CLDN6-encoding mRNA vaccine in patients with CLDN6-positive relapsed/refractory advanced solid tumors.

Olaparib Maintenance Provides Sustained OS Benefit in Newly Diagnosed, BRCA-Mutated, Advanced Ovarian Cancer

September 9th 2022

Two years of olaparib maintenance therapy elicited a long-term overall survival benefit vs placebo in patients with newly diagnosed advanced ovarian cancer harboring a BRCA mutation.

Olaparib Plus Bevacizumab Maintenance Therapy Provides OS Benefit in Advanced HRD-Positive Ovarian Cancer

September 9th 2022

Maintenance olaparib plus bevacizumab following first-line standard-of-care treatment improved overall survival in patients with newly diagnosed advanced ovarian cancer, particularly those with homologous recombination deficiency.